patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_785754 | REC_0017001 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.3 | 60 | male | 1 | 16 | 7.2 | 5 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:36:01.979773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865000 | REC_0017002 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 18.9 | 59 | male | 0 | 11 | 5.6 | 2 | alectinib 600 mg BID | 12.6 | true | MSI-H | 2026-03-15T05:36:01.980276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950791 | REC_0017003 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.3 | 72 | female | 1 | 12 | 6.2 | 5 | osimertinib 80 mg daily | 20.3 | true | MSI-H | 2026-03-15T05:36:01.980714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864967 | REC_0017004 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 7.4 | 67 | male | 1 | 16 | 5 | 6 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:36:01.981103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849347 | REC_0017005 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 5.7 | 90 | male | 2 | 18 | 3.9 | 2 | osimertinib 80 mg daily | 20.8 | true | MSS | 2026-03-15T05:36:01.981703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964751 | REC_0017006 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.5 | 74 | female | 2 | 32 | 3.5 | 1 | pembrolizumab 200 mg q3w | 25.7 | false | MSS | 2026-03-15T05:36:01.982148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335071 | REC_0017007 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 15.5 | 63 | male | 0 | 13 | 6 | 8 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.982543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115558 | REC_0017008 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.2 | 64 | male | 1 | 17 | 4.6 | 1 | alectinib 600 mg BID | 20.6 | false | MSS | 2026-03-15T05:36:01.982953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740357 | REC_0017009 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.4 | 71 | female | 1 | 12 | 6.8 | 7 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:36:01.983323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233473 | REC_0017010 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 15.8 | 77 | female | 2 | 15 | 4.7 | 1 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:36:01.983680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514620 | REC_0017011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.9 | 74 | female | 2 | 21 | 5.1 | 7 | entrectinib 600 mg daily | 5 | true | MSS | 2026-03-15T05:36:01.984058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267189 | REC_0017012 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 7.7 | 53 | male | 0 | 10 | 4 | 2 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:01.984477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670275 | REC_0017013 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.4 | 76 | female | 1 | 12 | 2.7 | 5 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:01.984871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334121 | REC_0017014 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.5 | 68 | female | 0 | 21 | 5.3 | 6 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:36:01.985243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777720 | REC_0017015 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.2 | 69 | female | 0 | 12 | 5.3 | 8 | sotorasib 960 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:36:01.985609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770393 | REC_0017016 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 19.7 | 75 | female | 1 | 6 | 6.4 | 7 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:36:01.985988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819934 | REC_0017017 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 35 | 5.5 | 72 | female | 1 | 23 | 6.6 | 2 | pembrolizumab 200 mg q3w | 14.4 | false | MSS | 2026-03-15T05:36:01.986358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656262 | REC_0017018 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 7.8 | 71 | male | 1 | 22 | 5.4 | 7 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:01.986888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236998 | REC_0017019 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.3 | 69 | female | 1 | 10 | 7.3 | 5 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:36:01.987341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940552 | REC_0017020 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 7.7 | 59 | female | 0 | 20 | 5.1 | 6 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:01.987774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369892 | REC_0017021 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.7 | 71 | female | 2 | 23 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:36:01.988236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755743 | REC_0017022 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.7 | 66 | male | 1 | 15 | 7.4 | 4 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:01.988653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849553 | REC_0017023 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.7 | 59 | male | 0 | 8 | 4.8 | 8 | pembrolizumab 200 mg q3w | 7.8 | false | MSI-H | 2026-03-15T05:36:01.989039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902013 | REC_0017024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10 | 64 | male | 1 | 20 | 5.4 | 5 | alectinib 600 mg BID | 10.2 | true | MSI-H | 2026-03-15T05:36:01.989425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506534 | REC_0017025 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11.1 | 65 | female | 0 | 26 | 4.7 | 5 | alectinib 600 mg BID | 16.5 | false | MSI-H | 2026-03-15T05:36:01.989779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770026 | REC_0017026 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 21 | 54 | female | 0 | 13 | 7.1 | 5 | entrectinib 600 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:01.990115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839067 | REC_0017027 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.8 | 65 | male | 0 | 22 | 4.5 | 6 | sotorasib 960 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:36:01.990459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940819 | REC_0017028 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 8 | 64 | female | 1 | 9 | 6.5 | 1 | pembrolizumab 200 mg q3w | 31.4 | false | MSS | 2026-03-15T05:36:01.990821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504219 | REC_0017029 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.8 | 57 | female | 1 | 11 | 7.2 | 3 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:01.991187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192127 | REC_0017030 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12.4 | 72 | female | 0 | 14 | 5 | 1 | sotorasib 960 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:01.991496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390304 | REC_0017031 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.3 | 80 | female | 2 | 13 | 6 | 7 | sotorasib 960 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.991935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833702 | REC_0017032 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.8 | 75 | female | 2 | 47 | 4.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.1 | true | MSS | 2026-03-15T05:36:01.992340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412277 | REC_0017033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 4.8 | 73 | female | 3 | 4 | 8 | 4 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:01.992723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504264 | REC_0017034 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.7 | 61 | female | 0 | 35 | 4 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:36:01.993101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323515 | REC_0017035 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 39 | 15.1 | 56 | female | 1 | 12 | 5 | 0 | entrectinib 600 mg daily | 17.3 | false | MSS | 2026-03-15T05:36:01.993444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648365 | REC_0017036 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 10.1 | 79 | male | 1 | 22 | 5.2 | 4 | pembrolizumab 200 mg q3w | 13.6 | false | MSI-H | 2026-03-15T05:36:01.993750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781237 | REC_0017037 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 18.2 | 64 | male | 0 | 19 | 5.6 | 0 | osimertinib 80 mg daily | 39.9 | true | MSS | 2026-03-15T05:36:01.994055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805535 | REC_0017038 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9 | 72 | female | 2 | 19 | 3.8 | 1 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:36:01.994356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796421 | REC_0017039 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.8 | 71 | female | 2 | 5 | 3.9 | 1 | alectinib 600 mg BID | 16.8 | true | MSS | 2026-03-15T05:36:01.994683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770439 | REC_0017040 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.8 | 58 | female | 0 | 54 | 7.2 | 5 | pembrolizumab 200 mg q3w | 14.4 | false | MSS | 2026-03-15T05:36:01.995010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921984 | REC_0017041 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 3 | 67 | female | 1 | 13 | 6.7 | 6 | osimertinib 80 mg daily | 4.4 | true | MSS | 2026-03-15T05:36:01.995308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819810 | REC_0017042 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.9 | 59 | female | 0 | 50 | 5.6 | 7 | pembrolizumab 200 mg q3w | 16 | true | MSS | 2026-03-15T05:36:01.995605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597611 | REC_0017043 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.5 | 53 | female | 0 | 13 | 7.3 | 5 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:36:01.995907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795581 | REC_0017044 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 3.8 | 70 | female | 1 | 14 | 6.4 | 2 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:36:01.996403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767895 | REC_0017045 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 7 | 61 | female | 1 | 19 | 5 | 5 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:36:01.996785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971050 | REC_0017046 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 5.8 | 84 | female | 2 | 3 | 5.7 | 5 | alectinib 600 mg BID | 9.6 | true | MSS | 2026-03-15T05:36:01.997134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982313 | REC_0017047 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 7.6 | 69 | male | 0 | 17 | 4.6 | 1 | alectinib 600 mg BID | 27.9 | false | MSS | 2026-03-15T05:36:01.997456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871843 | REC_0017048 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.9 | 62 | female | 0 | 45 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:36:01.997806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931778 | REC_0017049 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 5.5 | 77 | female | 1 | 12 | 7 | 6 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:36:01.998153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765805 | REC_0017050 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.8 | 76 | female | 2 | 15 | 4.8 | 6 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.998526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795858 | REC_0017051 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 9.7 | 69 | female | 0 | 19 | 6.5 | 5 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:01.998898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338140 | REC_0017052 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12.9 | 54 | female | 0 | 13 | 7.5 | 7 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:36:01.999262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442991 | REC_0017053 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.5 | 69 | female | 0 | 12 | 4.8 | 6 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:01.999638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113141 | REC_0017054 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.7 | 70 | female | 0 | 9 | 4.1 | 5 | sotorasib 960 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:02.000021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624430 | REC_0017055 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8 | 67 | male | 0 | 21 | 6.3 | 6 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:36:02.000600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148200 | REC_0017056 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 6.7 | 70 | male | 1 | 8 | 3.3 | 7 | osimertinib 80 mg daily | 5.3 | false | MSS | 2026-03-15T05:36:02.000997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495462 | REC_0017057 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 39 | 13.2 | 72 | female | 2 | 21 | 6.1 | 2 | osimertinib 80 mg daily | 21.9 | false | MSS | 2026-03-15T05:36:02.001531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368775 | REC_0017058 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.5 | 69 | female | 0 | 7 | 6.6 | 7 | alectinib 600 mg BID | 4.2 | false | MSI-H | 2026-03-15T05:36:02.001917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927326 | REC_0017059 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.3 | 72 | female | 2 | 42 | 2.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:36:02.002294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712274 | REC_0017060 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 15 | 71 | female | 0 | 3 | 6.8 | 6 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:02.002692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419212 | REC_0017061 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12 | 58 | male | 1 | 5 | 8 | 1 | sotorasib 960 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:36:02.003081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363473 | REC_0017062 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.1 | 68 | female | 1 | 10 | 5.4 | 2 | sotorasib 960 mg daily | 11.9 | true | MSI-H | 2026-03-15T05:36:02.003480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550905 | REC_0017063 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 14.3 | 74 | female | 1 | 21 | 5.9 | 2 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:36:02.003852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568001 | REC_0017064 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.3 | 64 | male | 1 | 9 | 5.8 | 2 | osimertinib 80 mg daily | 23.6 | true | MSI-H | 2026-03-15T05:36:02.004286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973203 | REC_0017065 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.2 | 72 | female | 2 | 14 | 6.3 | 2 | alectinib 600 mg BID | 14.3 | true | MSS | 2026-03-15T05:36:02.004731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607044 | REC_0017066 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.9 | 78 | male | 1 | 10 | 4.1 | 2 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:02.005159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787710 | REC_0017067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11 | 70 | female | 2 | 18 | 5.5 | 1 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:36:02.005551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138226 | REC_0017068 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.7 | 67 | female | 1 | 5 | 6 | 8 | osimertinib 80 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:36:02.005941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468887 | REC_0017069 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.1 | 66 | female | 1 | 13 | 5.9 | 6 | alectinib 600 mg BID | 14.4 | true | MSS | 2026-03-15T05:36:02.006303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282794 | REC_0017070 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.7 | 64 | female | 0 | 16 | 7.8 | 9 | sotorasib 960 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:36:02.006872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466775 | REC_0017071 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.9 | 69 | female | 1 | 66 | 3.8 | 4 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:02.007274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453454 | REC_0017072 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 35 | 10.4 | 64 | male | 1 | 26 | 5.1 | 0 | entrectinib 600 mg daily | 28.4 | false | MSS | 2026-03-15T05:36:02.007635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160362 | REC_0017073 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 11.1 | 67 | female | 1 | 19 | 4.9 | 1 | entrectinib 600 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:02.007998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390688 | REC_0017074 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16 | 73 | female | 1 | 18 | 5.7 | 6 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:02.008592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465449 | REC_0017075 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11 | 80 | female | 1 | 7 | 6.6 | 4 | entrectinib 600 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:02.008991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743976 | REC_0017076 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 21 | 16.2 | 54 | female | 0 | 20 | 6.4 | 0 | pembrolizumab 200 mg q3w | 22 | true | MSI-H | 2026-03-15T05:36:02.009363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852927 | REC_0017077 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 9 | 77 | male | 2 | 69 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:36:02.009734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638907 | REC_0017078 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 7.9 | 74 | female | 1 | 7 | 7 | 6 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:02.010101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874937 | REC_0017079 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13 | 60 | male | 0 | 8 | 4.1 | 2 | entrectinib 600 mg daily | 23.4 | true | MSS | 2026-03-15T05:36:02.010417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633053 | REC_0017080 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.8 | 67 | female | 1 | 58 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.1 | true | MSS | 2026-03-15T05:36:02.010730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768119 | REC_0017081 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18.7 | 82 | female | 1 | 5 | 4.4 | 4 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:02.011071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913232 | REC_0017082 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.3 | 69 | female | 0 | 16 | 7.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:36:02.011449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442806 | REC_0017083 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 6.4 | 62 | male | 1 | 5 | 4.1 | 2 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:36:02.012019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481422 | REC_0017084 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 7.8 | 56 | male | 1 | 11 | 7 | 1 | osimertinib 80 mg daily | 20.6 | true | MSS | 2026-03-15T05:36:02.012490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702459 | REC_0017085 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 4.8 | 53 | female | 0 | 68 | 4.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:36:02.012861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379149 | REC_0017086 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 12.6 | 68 | female | 1 | 0 | 5 | 5 | pembrolizumab 200 mg q3w | 8.5 | false | MSI-H | 2026-03-15T05:36:02.013245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707549 | REC_0017087 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.2 | 74 | female | 1 | 3 | 6.4 | 6 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:02.013624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434095 | REC_0017088 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 5.1 | 65 | male | 0 | 19 | 5.7 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:02.013999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382571 | REC_0017089 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.6 | 78 | female | 2 | 50 | 4.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 5.6 | true | MSS | 2026-03-15T05:36:02.014367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532714 | REC_0017090 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.6 | 56 | male | 0 | 15 | 7 | 6 | osimertinib 80 mg daily | 16 | true | MSI-H | 2026-03-15T05:36:02.014743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504044 | REC_0017091 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 1.5 | 67 | female | 1 | 19 | 5.5 | 5 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:02.015083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127235 | REC_0017092 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.9 | 70 | female | 1 | 16 | 4.3 | 2 | entrectinib 600 mg daily | 26.1 | false | MSS | 2026-03-15T05:36:02.015466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414579 | REC_0017093 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.5 | 56 | female | 1 | 43 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.5 | false | MSS | 2026-03-15T05:36:02.015842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563760 | REC_0017094 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.4 | 66 | female | 1 | 32 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:36:02.016346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497756 | REC_0017095 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 12.6 | 69 | female | 1 | 10 | 3.4 | 6 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:02.016775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412322 | REC_0017096 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 9.1 | 90 | female | 2 | 29 | 6 | 1 | sotorasib 960 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:02.017441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628944 | REC_0017097 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 16.6 | 64 | female | 0 | 26 | 6 | 2 | entrectinib 600 mg daily | 20.7 | true | MSS | 2026-03-15T05:36:02.017843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596108 | REC_0017098 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 9.7 | 65 | male | 0 | 4 | 5 | 1 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:02.018216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252534 | REC_0017099 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12 | 82 | female | 3 | 4 | 5.4 | 4 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:36:02.018595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242015 | REC_0017100 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.4 | 72 | male | 1 | 8 | 4.8 | 5 | osimertinib 80 mg daily | 18.2 | true | MSS | 2026-03-15T05:36:02.018942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.